98. 好酸球性消化管疾患 Eosinophilic gastrointestinal disease Clinical trials / Disease details


臨床試験数 : 172 薬物数 : 149 - (DrugBank : 39) / 標的遺伝子数 : 38 - 標的パスウェイ数 : 135

  
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-003226-23-DE
(EUCTR)
05/05/202121/12/2020A study evaluating the efficacy and safety of Etrasimod in the treatment of patients with eosinophilic esophagitisA Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Etrasimod in Adult Subjects with Eosinophilic Esophagitis - VOYAGE Eosinophilic Esophagitis (EoE)
MedDRA version: 20.1;Level: LLT;Classification code 10064220;Term: Eosinophilic esophagitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: Etrasimod
Product Code: APD334
INN or Proposed INN: etrasimod L-arginine
Other descriptive name: AR401959 L-arginine
Product Name: Etrasimod
Product Code: APD334
INN or Proposed INN: etrasimod L-arginine
Other descriptive name: AR401959 L-arginine
Arena Pharmaceuticals Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
96Phase 2United States;France;Spain;Belgium;Australia;Netherlands;Germany;Switzerland
2EUCTR2020-003226-23-NL
(EUCTR)
22/02/202126/11/2020A study evaluating the efficacy and safety of Etrasimod in the treatment of patients with eosinophilic esophagitisA Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Etrasimod in Adult Subjects with Eosinophilic Esophagitis - VOYAGE Eosinophilic Esophagitis (EoE)
MedDRA version: 20.1;Level: LLT;Classification code 10064220;Term: Eosinophilic esophagitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: Etrasimod
Product Code: APD334
INN or Proposed INN: etrasimod L-arginine
Other descriptive name: AR401959 L-arginine
Product Name: Etrasimod
Product Code: APD334
INN or Proposed INN: etrasimod L-arginine
Other descriptive name: AR401959 L-arginine
Arena Pharmaceuticals Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
96Phase 2United States;Belgium;Spain;Australia;Germany;Netherlands;Switzerland
3EUCTR2020-003226-23-BE
(EUCTR)
02/02/202123/11/2020A study evaluating the efficacy and safety of Etrasimod in the treatment of patients with eosinophilic esophagitisA Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Etrasimod in Adult Subjects with Eosinophilic Esophagitis - VOYAGE Eosinophilic Esophagitis (EoE)
MedDRA version: 20.1;Level: LLT;Classification code 10064220;Term: Eosinophilic esophagitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: Etrasimod
Product Code: APD334
INN or Proposed INN: etrasimod L-arginine
Other descriptive name: AR401959 L-arginine
Product Name: Etrasimod
Product Code: APD334
INN or Proposed INN: etrasimod L-arginine
Other descriptive name: AR401959 L-arginine
Arena Pharmaceuticals Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
96Phase 2United States;France;Spain;Belgium;Australia;Netherlands;Germany;Switzerland
4NCT04682639
(ClinicalTrials.gov)
December 15, 202019/12/2020A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic EsophagitisA Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Etrasimod in Adult Subjects With Eosinophilic EsophagitisEosinophilic EsophagitisDrug: Etrasimod;Drug: PlaceboPfizerArena is a wholly owned subsidiary of PfizerActive, not recruiting18 Years65 YearsAll108Phase 2United States;Australia;Belgium;Netherlands;Spain;Switzerland;Germany